Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation

NCT01003938 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01003938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01003938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2009
Completion date
December 31, 2012
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer